Dr. Linda Black on Fountain Report: Stem Cells, FDA Pathways, and the Future of Veterinary Medicine

In the interview, Dr. Black explains how ready-to-use stem cell therapies differ from traditional treatments by targeting the root cause of disease rather than just managing symptoms. She highlights Gallant’s lead investigational therapy for refractory feline chronic gingivostomatitis, now on track for FDA approval, and previews a robust pipeline including therapies for osteoarthritis and other chronic conditions in pets.

From Fountain Report Insights
A Q&A with Dr. Linda Black, CEO of Gallant

Dr. Black emphasizes that standardized, FDA-regulated stem cell therapies will give veterinarians new options that are easy to integrate into everyday practice—restoring health at the source and reshaping the standard of care for years to come.